Primary prevention with pravastatin in men with hypercholesterolaemia prevented cardiovascular disease with a number needed to treat of 31.4, at a discounted cost of £20,375 per life year gained.
Is pravastatin cost-effective for primary prevention of cardiovascular disease in men with hypercholesterolaemia?
Primary prevention with pravastatin in men with hypercholesterolemia provides substantial clinical benefit at a reasonable cost, especially in high-risk subgroups.
Effect estimate: NNT 31.4
Abstract Objective: To estimate the economic efficiency of using pravastatin to prevent the transition from health to cardiovascular disease in men with hypercholesterolaemia. Design: Economic benefit analysis based on data from the West of Scotland coronary prevention study. Treatment specific hazards of developing cardiovascular disease according to various definitions were estimated. Scottish record linkage data provided disease specific survival. Cost estimates were based on extracontractual tariffs and event specific average lengths of stay calculated from the West of Scotland coronary prevention study. Subjects: Men with hypercholesterolaemia similar to the subjects in the West of Scotland coronary prevention study. Main outcome: Cost consequences, the number of transitions from health to cardiovascular disease prevented, the number needed to start treatment, and cost per life year gained. Results: If 10 000 of these men started taking pravastatin, 318 of them would not make the transition from health to cardiovascular disease (number needed to treat, 31.4), at a net discounted cost of £20m over 5 years. These benefits imply an undiscounted gain of 2460 years of life, and thus £8121 per life year gained, or £20 375 per life year gained if benefits are discounted. Restriction to the 40% of men at highest risk reduces the number needed to treat to 22.5 (£5601 per life year gained (undiscounted) and £13 995 per life year gained (discounted)). Conclusions: In subjects without evidence of prior myocardial infarction but who have hypercholesterolaemia, the use of pravastatin yields substantial health benefits at a cost that is not prohibitive overall and can be quite efficient in selected high risk subgroups. Key messages The West of Scotland coronary prevention study showed that pravastatin can prevent cardiovascular disease in men with hypercholesterolaemia So far, reports have deemed this prevention unjustified due to adverse economic implications This analysis, based on data from the West of Scotland coronary prevention study and extensive data from the Scottish record linkage system, shows that using pravastatin in this way is worth considering because of its substantial clinical benefit at a reasonable cost Practitioners must now consider using pravastatin to prevent cardiovascular disease in men with hypercholesterolaemia Increased economic efficiency may be obtained by restricting prevention to patients with additional risk factors
Jaime et al. (Sat,) conducted a other in Hypercholesterolaemia (n=6,595). Pravastatin vs. Placebo was evaluated on Transition from health to cardiovascular disease (NNT 31.4). Primary prevention with pravastatin in men with hypercholesterolaemia prevented cardiovascular disease with a number needed to treat of 31.4, at a discounted cost of £20,375 per life year gained.